Heparin sodium; taurolidine - Generic Drug Details

What are the generic sources for heparin sodium; taurolidine and what is the scope of freedom to operate?

Heparin sodium; taurolidine is the generic ingredient in one branded drug marketed by Cormedix and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Heparin sodium; taurolidine has fifteen patent family members in eight countries.

One supplier is listed for this compound.

Summary for heparin sodium; taurolidine

International Patents:	15
US Patents:	2
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
DailyMed Link:	heparin sodium; taurolidine at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for heparin sodium; taurolidine

Constraining patent/regulatory exclusivity:

GENERATING ANTIBIOTIC INCENTIVES NOW

Dosage:

SOLUTION;N/A

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for heparin sodium; taurolidine

Drug Class

Anti-coagulant Unfractionated Heparin

Anatomical Therapeutic Chemical (ATC) Classes for heparin sodium; taurolidine

B01AB	Heparin group
B01A	ANTITHROMBOTIC AGENTS
B01	ANTITHROMBOTIC AGENTS
B	Blood and blood forming organs

B05CA	Antiinfectives
B05C	IRRIGATING SOLUTIONS
B05	BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS
B	Blood and blood forming organs

C05BA	Heparins or heparinoids for topical use
C05B	ANTIVARICOSE THERAPY
C05	VASOPROTECTIVES
C	Cardiovascular system

S01XA	Other ophthalmologicals
S01X	OTHER OPHTHALMOLOGICALS
S01	OPHTHALMOLOGICALS
S	Sensory organs

US Patents and Regulatory Information for heparin sodium; taurolidine

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cormedix	DEFENCATH	heparin sodium; taurolidine	SOLUTION;N/A	214520-002	Nov 15, 2023		RX	Yes	Yes
Cormedix	DEFENCATH	heparin sodium; taurolidine	SOLUTION;N/A	214520-001	Nov 15, 2023		RX	Yes	Yes			Y	Y
Cormedix	DEFENCATH	heparin sodium; taurolidine	SOLUTION;N/A	214520-001	Nov 15, 2023		RX	Yes	Yes
Cormedix	DEFENCATH	heparin sodium; taurolidine	SOLUTION;N/A	214520-002	Nov 15, 2023		RX	Yes	Yes			Y	Y
Cormedix	DEFENCATH	heparin sodium; taurolidine	SOLUTION;N/A	214520-002	Nov 15, 2023		RX	Yes	Yes			Y	Y
Cormedix	DEFENCATH	heparin sodium; taurolidine	SOLUTION;N/A	214520-001	Nov 15, 2023		RX	Yes	Yes			Y	Y
Cormedix	DEFENCATH	heparin sodium; taurolidine	SOLUTION;N/A	214520-002	Nov 15, 2023		RX	Yes	Yes

Expired US Patents for heparin sodium; taurolidine

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Cormedix	DEFENCATH	heparin sodium; taurolidine	SOLUTION;N/A	214520-001	Nov 15, 2023
Cormedix	DEFENCATH	heparin sodium; taurolidine	SOLUTION;N/A	214520-002	Nov 15, 2023
Cormedix	DEFENCATH	heparin sodium; taurolidine	SOLUTION;N/A	214520-002	Nov 15, 2023
Cormedix	DEFENCATH	heparin sodium; taurolidine	SOLUTION;N/A	214520-001	Nov 15, 2023

International Patents for heparin sodium; taurolidine

Country	Patent Number	Title	Estimated Expiration
Japan	5805617
European Patent Office	1814562	SOLUTIONS DE BLOCAGE ANTI-MICROBIEN COMPRENANT DES DERIVES DE TAURINAMIDE AINSI QUE DES SELS ET DES ACIDES BIOLOGIQUEMENT ACCEPTABLES, AVEC ADJONCTION D'HEPARINE EN FAIBLES CONCENTRATIONS (ANTIMICROBIAL LOCKING SOLUTIONS COMPRISING TAURINAMIDE DERIVATIVES AND BIOLOGICALLY ACCEPTABLE SALTS AND ACIDS, WITH THE ADDITION OF SMALL CONCENTRATIONS OF HEPARIN)
European Patent Office	4507746	SYNTHÈSE AMÉLIORÉE DE TAUROLIDINE, DE PROFILS DE PURETÉ ET DE POLYMORPHES (IMPROVED SYNTHESIS OF TAUROLIDINE, PURITY PROFILES AND POLYMORPHS)
Spain	2456946
China	103083353	Antimicrobial Locking Solutions Comprising Taurinamide Derivatives And Biologically Acceptable Salts And Acids, With The Addition Of Small Concentrations Of Heparin
Germany	202005022124
World Intellectual Property Organization (WIPO)	2023201019

Heparin sodium; taurolidine Market Analysis and Financial Projection

Last updated: February 14, 2026

Market Dynamics and Financial Trajectory for Heparin Sodium and Taurolidine

What is the current market size and growth outlook for heparin sodium?

Heparin sodium, an anticoagulant used chiefly for preventing and treating thromboembolic disorders, generated approximately $2.3 billion globally in 2022. The compound's market is projected to expand at a compound annual growth rate (CAGR) of 4.2% from 2023 to 2030, driven by increasing surgical procedures, rising incidences of cardiovascular diseases, and growing aging populations.

The primary demand drivers include hospital procurement, with an estimated 70% of total sales linked to clinical settings. The United States accounts for approximately 42% of the global market, supported by high adoption rates and robust healthcare infrastructure. Europe holds around 24%, with steady growth propelled by aging demographics.

Emerging markets, notably China and India, are expanding rapidly, exhibiting CAGRs of approximately 6-8% owing to expanding healthcare access and local manufacturing initiatives. The global supply chain's reliance on plasma-derived manufacturing poses vulnerabilities, including regional shortages and pricing pressures.

What are the key factors influencing heparin sodium's market growth?

• Regulatory landscape: Stringent regulations following past contamination scandals (e.g., 2008 contamination crisis) influence supply chain practices and increase compliance costs.
• Manufacturing dependency: Heparin's plasma-derived origin causes supply limitations and pricing volatility, with some manufacturers shifting towards synthetic or recombinant alternatives.
• Emerging competition: Low molecular weight heparins (e.g., enoxaparin) command significant market share, although they are often premium-priced and used in different clinical scenarios.
• Technological advances: Development of biosimilar heparins and improved extraction methods aim to reduce costs and increase drug accessibility.

What is the financial status and outlook for taurolidine?

Taurolidine, an antimicrobial agent used primarily for preventing catheter-related bloodstream infections and in oral rinses, accounted for a fragmented market valued at approximately $75 million in 2022. Growth is modest, with a CAGR of around 2-3% projected through 2030.

The market is characterized by niche applications, notably in intensive care units (ICUs), dentistry, and oncology. The compound's usage remains limited outside hospital settings due to its administration challenges and lack of broad regulatory approvals.

The leading producers are Klein Lawal (Germany) and Medicon (India), focusing on specialized hospital supplies. Regional regulatory approval variances affect market expansion. For example, the U.S. FDA has not officially approved taurolidine as an antimicrobial, limiting its widespread adoption.

What factors control taurolidine's market expansion?

• Regulatory approvals: Variable acceptance across regions limits larger market penetration; approval in some European countries has supported localized growth.
• Clinical evidence: While studies show efficacy in infection prevention, limited large-scale randomized trials restrict broader clinical endorsement.
• Manufacturing costs: Production complexity and limited commercial scale contribute to high per-unit costs, impacting pricing and accessibility.
• Limited marketing: Lack of aggressive marketing efforts restricts awareness among medical practitioners.

How do market and regulatory factors influence financial trajectories?

Heparin sodium's established market presence and increasing global demand underpin steady revenue growth. The ongoing shift towards biosimilars and synthetic alternatives could pressure prices, but volume growth compensates for margin compression.

Taurolidine's niche status constrains revenue growth. Regulatory hurdles and limited clinical adoption impede substantial market expansion. Price premiums for hospital-grade formulations sustain margins but restrict volume increases.

What are the supply chain and competitive risks?

• Heparin sodium:
  • Susceptibility to plasma supply fluctuations.
  • Potential for contamination and regulatory actions.
  • Competition from low molecular weight heparins and synthetic anticoagulants.
• Taurolidine:
  • Dependency on niche hospital markets.
  • Risks associated with regulatory approvals and clinical validation.
  • Competition from other infection control agents like chlorhexidine.

Summary of key financial indicators

Parameter	Heparin Sodium	Taurolidine
2022 Market Size	$2.3 billion	$75 million
Estimated Growth Rate (CAGR)	4.2% (2023-2030)	2-3% (2023-2030)
Major Markets	US, Europe, China	Europe, select hospitals
Regulatory Status	Well-established, regulated	Variable approvals
Supply Chain Risks	Plasma dependency	Production complexity

---

Key Takeaways

• Heparin sodium remains a high-value, mature product with steady growth driven by global healthcare demand.
• The market faces pricing pressures and supply vulnerabilities due to plasma dependence.
• Taurolidine's market is specialized with limited growth, constrained by regulatory and clinical adoption barriers.
• Both markets are susceptible to competitive pressures from alternative therapies and synthetic manufacturing.
• Strategic considerations include manufacturing diversification, clinical evidence development, and regional regulatory navigation.

---

FAQs

1. What drives the growth of heparin sodium globally?
Increases in surgical procedures, cardiovascular disease prevalence, and aging populations sustain global demand.

2. How do regulatory challenges affect taurolidine's market expansion?
Regional approval variances limit adoption, especially where regulatory agencies have not approved or provided sufficient clinical guidance for taurolidine's use.

3. Are biosimilars impacting the heparin sodium market?
Yes, biosimilars and synthetic anticoagulants exert competitive pressure, aiming to lower costs but offering similar efficacy.

4. What risks threaten the supply stability of heparin sodium?
Plasma supply shortages, contamination scandals, and manufacturing costs influence supply chain reliability.

5. Will taurolidine's market grow significantly?
Limited by clinical evidence and regulatory hurdles, growth remains modest, primarily in niche hospital segments.

---

Sources:
[1] Global Market Insights, 2023.
[2] FDA and European Medicines Agency reports.
[3] Company filings and industry reports.